
    
      1200 patients with stage Ⅳ colorectal cancer,who had received surgery and chemotherapy,will
      be randomly divided into group A（receive CIK plus S-1 and Bevacizumab ) or group B（just
      receive S-1 and Bevacizumab),and the randomize ratio will be 1:1. Patients in group A will
      receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group
      B will receive only S-1 and Bevacizumab (continuous) .
    
  